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Abstract
Background: Bacterial sortases are transpeptidases that covalently anchor surface proteins to the peptidoglycan of
the Gram-positive cell wall. Sortase protein anchoring is mediated by a conserved cell wall sorting signal on the
anchored protein, comprising of a C-terminal recognition sequence containing an “LPXTG-like” motif, followed by a
hydrophobic domain and a positively charged tail.
Results: We report that Clostridium difficile strain 630 encodes a single sortase (SrtB). A FRET-based assay was used
to confirm that recombinant SrtB catalyzes the cleavage of fluorescently labelled peptides containing (S/P)PXTG
motifs. Strain 630 encodes seven predicted cell wall proteins with the (S/P)PXTG sorting motif, four of which are
conserved across all five C. difficile lineages and include potential adhesins and cell wall hydrolases. Replacement of
the predicted catalytic cysteine residue at position 209 with alanine abolishes SrtB activity, as does addition of the
cysteine protease inhibitor MTSET to the reaction. Mass spectrometry reveals the cleavage site to be between the
threonine and glycine residues of the (S/P)PXTG peptide. Small-molecule inhibitors identified through an in silico
screen inhibit SrtB enzymatic activity to a greater degree than MTSET.
Conclusions: These results demonstrate for the first time that C. difficile encodes a single sortase enzyme, which
cleaves motifs containing (S/P)PXTG in-vitro. The activity of the sortase can be inhibited by mutation of a cysteine
residue in the predicted active site and by small-molecule inhibitors.
Keywords: Clostridium difficile, Sortase, Cysteine protease, Fluorescence resonance energy transfer (FRET), Enzyme
kinetics, Enzyme inhibitors
Background
Sortases are membrane-bound cysteine transpeptidases
that anchor surface proteins to the peptidoglycan cell
wall in Gram-positive bacteria. Surface proteins anchored
via sortases are often essential virulence factors important
in colonization and invasion, evasion of the host immune
system, and nutrient acquisition. The sorting process is
mediated by a conserved C-terminal cell wall sorting sig-
nal on the anchored protein, comprised of a C-terminal
recognition sequence (often LPXTG, where X is any
amino acid), followed closely by a hydrophobic transmem-
brane domain and a positively charged tail [1]. A con-
served catalytic cysteine residue of the sortase cleaves the
LPXTG motif of the polypeptide between the threonine
and glycine residues and covalently attaches the protein to
the peptidoglycan [2-6].
There are six described sortase families, A-F, that
share amino acid similarity [7]. All catalyze similar trans-
peptidation reactions, but recognize different substrate
motifs and serve different functions within the cell. Class
A sortases (SrtA), such as the prototypical Staphylococcus
aureus Sortase A (SaSrtA), are considered housekeeping
sortases as they are capable of anchoring many function-
ally distinct proteins to the cell wall. SaSrtA, which recog-
nizes an LPXTG motif, is responsible for anchoring a
variety of surface proteins involved in adherence and im-
mune response evasion, and is essential for virulence in
animal models [8,9]. SrtA orthologues have been found
in the genomes of almost all Gram-positive bacteria
[8,10-16]. Class B sortases are functionally different from
class A in their substrate specificity. In S. aureus and B.
anthracis, the sortase B gene (srtB) is part of an iron-
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regulated locus isd (iron-responsive surface determinant)
responsible for heme-iron transport, and anchors the iron
transporter protein, IsdC, by recognizing an NPQTN
motif [17,18]. Though mutating srtB has no effect on es-
tablishing infection, SaSrtB is required for persistence of
the bacterium in mice [17].
Clostridium difficile, an anaerobic Gram-positive, spore-
forming bacillus, is the leading cause of hospital-acquired
infectious diarrhea in North America and Europe. In-
fection with C. difficile can result in a range of clinical
presentations, from mild self-limiting diarrhea to the
life-threatening pseudomembranous colitis (PMC), known
collectively as C. difficile infection (CDI) [19]. MLST stud-
ies have identified that the C. difficile population structure
forms at least five distinct lineages that are all associated
with CDI [20-22]. Complications of severe CDI can lead
to toxic megacolon, bowel perforation, sepsis and death in
up to 25% of cases [23]. Broad-spectrum antibiotic usage
is the greatest risk factor for development of CDI due to
the consequent disruption of the intestinal microflora.
Treatment of CDI with metronidazole and vancomycin
can exacerbate the problem by continuing to disrupt the
intestinal microflora. This leaves the patient susceptible to
relapse or re-infection. Approximately one third of pa-
tients experience CDI relapse following treatment, and
those who relapse have a greater risk of succumbing to
the infection [23]. A current imperative is the develop-
ment of therapies that selectively target C. difficile, whilst
leaving the intestinal microflora intact.
The C. difficile reference strain 630 encodes a single
predicted sortase, CD630_27180, which has high amino-
acid similarity with SrtB of S. aureus and B. anthracis
[24]. A second sortase encoded within the genome is
interrupted by a stop codon prior to the catalytic cyst-
eine and is considered a pseudogene. Thus, in contrast
to other Gram-positive bacteria, C. difficile appears to
have only a single functional sortase. As such, a com-
pound that inhibits the activity of C. difficile sortase
could target the pathogen without disrupting the numer-
ous Gram-negative bacteria that make up the intestinal
flora.
In this study, we demonstrate that the predicted sor-
tase encoded by CD630_27180 recognizes and cleaves
an (S/P)PXTG motif between the threonine and glycine
residues. The cleavage of this motif is dependent on the
conserved cysteine residue at position 209 in the pre-
dicted active site of the sortase. We have also identified
seven putative sortase substrates, all of which contain
the (S/P)PXTG motif. These substrates are conserved
among the five C. difficile lineages and include potential
adhesins, a 5’ nucleotidase, and cell wall hydrolases. Fur-
thermore, we identified a number of small-molecule in-
hibitors by means of an in silico screen that inhibit the
activity of the C. difficile SrtB.
Results
Conservation of the catalytically active residues of sortase
The genome sequence of C. difficile strain 630 previously
indicated the presence of a single copy of a sortase-like
protein, encoded by CD630_27180, based on the presence
of the sortase catalytic motif TLXTC [24]. We performed
BLAST searches (BlastP) to reveal the protein encoded
by CD630_27180 shares 32% and 34% amino acid iden-
tity with SrtB from S. aureus (SaSrtB) and B. anthracis
(BaSrtB), respectively. In addition to the TLXTC active
site, the catalytically essential histidine (His120 in SaSrtA)
and arginine (R197 in SaSrtA) residues [3,25,26] are con-
served in the C. difficile SrtB. A structural prediction ana-
lysis of SrtB was performed using Phyre2 Protein Fold
Recognition Server (http://www.sbg.bio.ic.ac.uk/phyre2/
html/page.cgi?id=index) [27], and the resulting alignment
suggests a high level of conservation between the pre-
dicted secondary structure of SrtB and the known crystal
structure of the BaSrtB [28] (Figure 1). Expression of C.
difficile SrtB was analysed in vitro using RT-PCR analysis
on strain 630, which confirmed that CD2718 is actively
transcribed during early exponential, late exponential and
stationary phases (Additional file 1: Figure S1).
The C. difficile population structure forms at least five
distinct clonal lineages that are all associated with hu-
man infection [20-22]. To determine whether SrtB is
conserved between C. difficile strains, representatives for
each of the five distinct clades were chosen for analysis
based on the availability of a fully annotated sequence:
C. difficile strains 630 for Clade 1, R20291 and CD196
(RT027) for Clade 2 [29], M68 and CF5 (RT017) for
Clade 3 [20], CD305 (RT023) for Clade 4 (unpublished,
WTSI), and M120 (RT078) for Clade 5 [20]. BLAST
searches of these representative strains show that srtB is
conserved across all five C. difficile lineages. A second
sortase-like gene in the 630 genome, classified as a pseu-
dogene because of an in frame stop codon prior to
the catalytic cysteine, is absent from the other four C.
difficile lineages.
Bioinformatic prediction of sortase substrates
A bioinformatics approach was used for the prelimi-
nary identification of sortase substrate proteins in C.
difficile strain 630. The predicted recognition sequence
for CD630_27180 has been proposed to be (S/P)PXTG by
Pallen et al. [11], and recently to also include the sequence
NVQTG, found in the surface- associated collagen bind-
ing protein CbpA, by Tulli et al. [30]. Putative proteins
were screened for the patterns (S/P)PXTG and NVQTG
at the C-terminus [11,30]. Putative candidates were then
assessed for the known features of a sortase substrate: a
predicted N-terminal signal peptide sequence, and a cell
wall sorting signal comprising of a potential transmem-
brane domain following the sortase recognition sequence,
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and at least two consecutive basic residues (arginine or
lysine) at the C-terminus [31-33].
Eight proteins satisfied our definition of a sortase sub-
strate in strain 630 (Table 1). The newly described C.
difficile collagen binding protein A, CbpA, is the only
protein containing the proposed NVQTG motif [30].
The remaining proteins contained one of four observed
variations of the (S/P)PXTG motif: SPKTG, PPKTG, and
SPSTG and SPQTG. These predicted C. difficile sortase
substrates are a diverse range of surface proteins that
include putative cell wall hydrolases, putative adhesins,
a collagen-binding protein, and a 5’ nucleotidase/phos-
phoesterase (Table 1). Transcriptional analysis per-
formed by RT-PCR confirmed that all eight predicted
substrate proteins are transcribed during growth in vitro
(Additional file 1: Figure S1B-I). The eight predicted
substrates are transcribed during all three growth pha-
ses examined, with the exception of CD630_25370 and
CD630_32460, which do not appear to be transcribed
during stationary phase. Four of these putative substrates
are conserved across all five C. difficile lineages: CD630_
01830, CD630_25370, CD630_27680, and CD630_28310.
Purified C. difficile SrtB cleaves (S/P)PXTG peptides
To determine whether C. difficile SrtB cleaves putative
substrates at the predicted motifs, FRET peptides were
designed based on the variations observed in the predicted
(S/P)PXTG motif (Table 2). Two residues upstream of the
Table 1 Identification of putative C. difficile SrtB substrates in strain 630
Protein Function C-terminal sorting signal
CD630_01830 Putative cell wall hydrolase MIHSPSTGKTVSVTSINSSYYTARFVTAKRIL
CD630_03860 Putative cell surface protein, collagen binding protein PSDSPKTGDNTNLYGLLALLLTSGAGLAGIFFYKRRKMKKS
CD630_25370 Putative membrane-associated 5'-nucleotidase/phosphoesterase KEKSPKTGDLGFSNSIIIFIVSSTLICLLNFNQKELKDKKSK
CD630_27680 Putative cell-wall hydrolase FIHSPQTGDVVKVTSMAPGTNYARRLITATRVLQ
CD630_28310 Putative adhesion, collagen binding protein PPVPPKTGDSTTIIGEILLVIGAIVGLIVLRRNKNTN
CD630_31450 Collagen binding protein, CbpA VGQNVQTGDQSNIMLDLALMFISLFFLIKNLTNKYLRRK
CD630_32460 Putative surface protein IVKSPKTGDETQLMSYVFISVIAICGLAYQCKIKRN
CD630_33920 Putative cell surface protein, collagen binding protein PSDSPKTGDSTNLMAFIVMLLVSGGGLAGTYLYKRRKMKKS
Bold = predicted sortase recognition sequence.
Bold and Italic = hydrophobic residues.
Italics only = positively charged residues.
Figure 1 Predicted C. difficile SrtB secondary structure. A structural alignment between the known crystal structure of BaSrtB [28] and the
predicted structure of C. difficile SrtB using the Phyre2 Protein Fold Recognition Server suggests a high degree of structural conservation. Top:
C. difficile SrtB predicted secondary structure and sequence. Bottom: BaSrtB sequence and known structure. Arrows indicate beta sheets, and
striped rectangles indicate alpha helixes. Amino acid positions relative to start position are indicated. The sortase active site signature sequence
TLXTC is boxed, as are the conserved essential histidine and arginine residues.
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motif were included, and two glycine residues were incor-
porated downstream, as this has been previously shown to
improve sortase cleavage efficiency in vitro [34]. Fluores-
cence of the Edans fluorophore within the peptides is
blocked when in close proximity to the fluorescent
quencher Dabcyl [35]. When the peptide is cleaved, the
Edans fluorophore is separated from Dabcyl, and a fluor-
escent signal is observed.
The N-terminal transmembrane domain of C. difficile
SrtB (residues 2–25) was replaced with a six-histidine
tag (SrtBΔN26) to improve soluble protein yield. SrtBΔN26
was expressed in E. coli NiCo21(DE3) and purified
by nickel affinity chromatography from cleared lysates
(Figure 2). Purified SrtBΔN26 was then incubated with a
FRET peptide containing the SPKTG sequence. An in-
crease in fluorescence was observed over time, indicat-
ing that cleavage of the SPKTG peptide occurred in the
presence of SrtBΔN26 over 48 hours (Figure 3). In addi-
tion to the SPKTG motif, SrtBΔN26 also cleaved peptides
containing the predicted substrate sequences PPKTG,
SPSTG, and SPQTG (Figure 4). SrtBΔN26 failed to cleave
the scrambled peptide sequences GSKTP, GPKTP, GSSTP
and GSQTP (Figure 4). Interestingly, SrtBΔN26 failed to
cleave peptides containing the LPETG and NPQTN mo-
tifs of SaSrtA and SaSrtB, respectively, and also failed to
cleave the proposed sortase recognition motif NVQTG
found in the C. difficile collagen binding protein, CbpA
[30] (Figure 4).
Analysis of FRET reaction
To investigate the importance of the cysteine residue in
the proposed active site of C. difficile SrtB, site-directed
mutagenesis was used to replace the cysteine residue at
position 209 with an alanine. When the resulting mutant
protein SrtBΔN26,C209A was incubated with the FRET
peptides, the fluorescent signal fell below the limits of
detection (Figure 5), indicating that the cysteine residue
at position 209 was essential for the activity of the C.
difficile SrtB. Cleavage in the FRET-based assay was also
inhibited by the addition of MTSET (Figure 5), a known
cysteine protease inhibitor and inhibitor of sortase func-
tion in S. aureus [36,37] and B. anthracis [15].
The cleavage of the SPKTG, PPKTG, and SPQTG mo-
tifs was enhanced at least two-fold by the addition of the
two native amino acids immediately downstream of this
sequon (data not shown). Analysis of the FRET reaction
with these modified peptides revealed that SrtBΔN26, clea-
ves these peptides between the T and G residues. MALDI
analysis of d-PVPPKTGDS-e peptide incubated with
SrtBΔN26 results in a peptide with a mass of 889 Da,
Table 2 FRET peptide details
Peptide sequence* Description
d-IHSPSTGGG-e Based on CD0183 sequence
d-IHGSSTPGG-e Control for above peptide
d-SDSPKTGGG-e Based on CD0386, CD3392 sequence
d-SDGSKTPGG-e Control for above peptide
d-IHSPQTGGG-e Based on CD2768 sequence
d-IHGSQTPGG-e Control for above peptide
d-PVPPKTGGG-e Based on CD2831 sequence
d-PVGPKTPGG-e Control for above peptide
d-GQNVQTGGG-e Based on CbpA sequence
d-QALPETGGG-e SaSrtA peptide
d-NPQTN-e SaSrtB peptide
d-IHSPSTGKT-e Based on CD0183 sequence
d-SDSPKTGDN-e Based on CD0386 sequence
d-IHSPQTGDV-e Based on CD2768 sequence
d-PVPPKTGDS-e Based on CD2831 sequence
*Where d is Dabcyl (4-([4-(dimethylamino)phenyl]azo)-benzoyl) and e is Edans
(5-((2-Aminoethyl)amino)naphthalene-1-sulfonic acid).
Figure 2 Expression and purification of SrtBΔN26. E. coli NiCo21(DE3) expressing SrtBΔN26, in which the N-terminal membrane anchor has been
replaced with a six-histidine tag, were lysed by sonication and cleared lysates purified by nickel affinity chromatography. A. Anti-his western
testing for expression of SrtBΔN26. Lane M: molecular mass marker, N: whole cell lysate of non-induced culture, I: whole cell lysate of culture
induced with 1 mM IPTG. B. Coomassie-stained SDS-PAGE analysis of SrtBΔN26 purification over an imidazole gradient. Lane L: molecular mass
marker, W: column wash, imidazole gradient indicated by grey triangle, arrows indicate the SrtBΔN26 protein.
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corresponding to the fragment d-PVPPKT-OH (Figure 6,
top). The peptide control, incubated without SrtBΔN26,
lacked this fragment (Figure 6, bottom). Cleavage between
the T and G residues for the d-SDSPKTGDN-e and d-
IHSPQTGDV-e peptides was also confirmed (data not
shown), indicating that C. difficile SrtB cleaves the (S/P)
PXTG motif between the same residues as other func-
tional sortases [4,15,38,39].
Kinetic measurements of SrtB activity
In order to calculate the in vitro kinetic parameters of
SrtBΔN26 for the d-SDSPKTGDN-e and d-PVPPKTGDS-e
peptides, we performed a kinetic analysis of the sortase-
catalyzed hydrolysis reaction. Figure 7A shows the pro-
gress curves of the SrtBΔN26 catalyzed hydrolysis reactions
at various d-SDSPKTGDN-e concentrations. For each
progress curve, the amount of fluorescent product (after
conversion from RFU to concentration) was approxi-
mately 5% of the initial substrate concentration. Within
the time period analyzed, the progress curves are linear, so
the steady state rate (V) was determined by fitting the data
to a linear function. Figure 7B shows V plotted against the
concentration of the peptide. Non-linear regression of
these data fitted to a modified Michaelis-Menten equation
incorporating substrate inhibition (Equation 1):
V ¼ Vmax⋅ S½ 
Km þ S½  þ S½ 
2
Ki
ð1Þ
Using SciPy 0.11.0 in Python 2.7.3, where Vmax is the
apparent maximal enzymatic velocity, Km is the apparent
Michaelis constant, and Ki is the apparent inhibitor dis-
sociation constant for unproductive substrate binding.
This resulted in a Km of 74.7 ± 48.2 μM and a Kcat of
1.1×10−3 ± 6×10−4 min−1 for d-SDSPKTGDN-e (Figure 7B).
This analysis was performed for d-PVPPKTGDS-e, result-
ing in a Km of 53.3 ± 25.6 μM and a Kcat of 8.3×10
−4 ±
3×10−4 min−1. SrtBΔN26 is subject to substrate inhibition; at
peptide concentrations greater than 30 μM, the rate of
SrtBΔN26 activity decreases. Substrate inhibition has previ-
ously been observed for other sortase enzymes in vitro,
and is not expected to be physiologically relevant [40].
Inhibiting SrtB activity
We sought to determine whether C. difficile SrtB could
be specifically targeted using small-molecule inhibitors.
The published crystal structure of the B. anthracis SrtB
(BaSrtB) [28] was used as a template for the selection of
potential C. difficile SrtB inhibitors. These orthologous
proteins show 70% identity and 90% similarity at the active
Figure 3 Cleavage of SPKTG peptide by recombinant SrtBΔN26.
Purified recombinant SrtBΔN26 was incubated with a FRET peptide
containing the SPKTG motif and fluorescence measured every hour
for the first eight hours, and also at 24 h, 36 h, and 48 h. An increase
in relative fluorescence units (arbitrary units) was observed,
compared with the peptide incubated alone, indicating that SrtBΔN26
mediated cleavage of the SPKTG peptide occurred over a period of
48 hours. Error bars represent the standard error of the mean.
Figure 4 SrtBΔN26 substrate specificity. Purified recombinant SrtBΔN26 protein was incubated with a range of peptide sequences to investigate
its substrate specificity. The motifs SPKTG, PPKTG, SPSTG and SPQTG were all recognized and cleaved following incubation with SrtBΔN26. The
scrambled peptide sequences GSKTP, GPKTG, GSSTP, and GSQTP serve as controls for the cleavage specificity of SrtBΔN26. The sequences LPETG
and NPQTN, corresponding to the motifs recognized by S. aureus sortase A and B, respectively, do not appear to be substrates for SrtBΔN26.
SrtBΔN26 also failed to cleave the proposed sorting signal NVQTG from recently characterized collagen binding protein, CbpA. Bars indicate the
mean, and error bars represent the standard error (**corresponds to p < 0.01).
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site, and their differences are confined to the periphery
of the active site. The proprietary LeadBuilder virtual-
screening method (Domainex Ltd) was used to interrogate
the PROTOCATS database of potential protease inhibitors
with pharmacophoric and docking filters derived from
analysis of the BaSrtB crystal structure. PROTOCATS
comprises 80,000 commercially-available compounds that
may form reversible transition-state-like complexes with
protease enzymes. Compounds in PROTOCATS contain a
carbonyl group which is activated to make a fully revers-
ible complex with the active-site serine/cysteine group by
virtue of adjacent moderately electron-withdrawing sub-
stituents, which are not leaving groups. Some examples of
these functional groups are α-ketoamides and aryl ke-
tones. Figure 8A shows one of the identified compounds
docking within the active site structure of BaSrtB.
Compounds identified in this screen as potential SrtB
inhibitors were tested alongside the cysteine protease
inhibitor MTSET at a range of concentrations in the
FRET-based assay using the d-PVPPKTGDS-e peptide
to compare IC50 values. Addition of MTSET reduced
SrtBΔN26 activity to below the limits of detection at
concentrations of 500 μM and greater. MTSET exhib-
ited an IC50 of 286.7 ± 16.6 μM (Figure 8B). A panel
of potential C. difficile SrtB inhibitors were screened
for inhibition of SrtBΔN26 activity. The most effective
of the 62 compounds were LSHTM40, LSHTM50,
and LSHTM52. They had IC50 values below 100 μM
(Figure 8B, Table 3), at 63.1 ± 8.8 μM, 60.1 ± 4.7 μM,
and 44.1 ± 6.9 μM, respectively, showing a good effi-
cacy against C. difficile SrtB activity.
Discussion
C. difficile infection is invariably associated with the dis-
ruption of the normal intestinal microflora by the ad-
ministration of broad spectrum antibiotics. Thus there is
a pressing need to develop therapies that selectively
target C. difficile while leaving the intestinal microflora
intact. The C. difficile reference strain 630 encodes a sin-
gle predicted sortase, CD630_27180, which has strong
amino acid similarity with SrtB of S. aureus and B. anth-
racis [24]. Sortase substrates frequently contribute to-
ward pathogenesis via their involvement in attachment
to specific tissues during infection [17,41-44], as well as
the bacteria’s ability to evade the immune response of
the host [32,36]. Sortases, although not essential for
growth or viability of the organism, are often essential
for virulence in Gram-positive organisms; inactivation of
sortases reduces colonization in mice [8,13,44,45], and
decreases adhesion and invasion in vitro [8,10,14,46,47].
Sortases and their substrates are considered promising
targets for the development of new anti-infective com-
pounds [10,14,48]. Unusually for Gram-positive bacteria,
C. difficile appears to possess a single sortase enzyme
that is likely to be important for the viability of the pa-
thogen as we have been unable to construct a C. difficile
strain 630 SrtB defined mutant (unpublished data). Inhi-
biting the C. difficile sortase could prove to be a strategy
to specifically target C. difficile.
In this study, we cloned, expressed and characterized
the sortase encoded by CD630_27180 of C. difficile 630,
a predicted class B sortase (SrtB). Sortase nomenclature
is based on sequence similarity to the known classes of
sortase, A-F [7]. Sortases of class B typically are involved
in heme-iron uptake and tend to be expressed in op-
erons with their substrates [17,18]. Genes encoding class
A sortases are not found in proximity to their substrates,
which consist of a variety of surface proteins with di-
verse biological functions. Several exceptions to these
rules have already been described, notably a class B sor-
tase that polymerizes pilin subunits in S. pyogenes [49],
and a class E sortase from C. diphtheriae that serves a
housekeeping function [50]. The potential C. difficile sor-
tase substrates identified in this paper comprise a diverse
Figure 5 SrtBΔN26 activity requires a cysteine residue at position 209. To determine if SrtBΔN26 activity depended on the cysteine residue at
position 209, a C209A substitution was made to create SrtBΔN26,C209A. This enzyme was inactive against the FRET peptides when compared with
SrtBΔN26. Addition at 5 mM of the cysteine protease inhibitor, MTSET, to the reaction also eliminates activity (**corresponds to p < 0.01).
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range of surface proteins, suggesting that SrtB may serve
as a housekeeping sortase in C. difficile, a function usually
reserved for class A sortases.
These potential sortase substrates in C. difficile strain
630 comprise of seven proteins, all containing an (S/P)
PXTG motif, that are predicted to be surface localized
and are conserved across C. difficile strains. Recently it
was proposed that a C. difficile collagen binding protein,
CbpA, may be sorted to the cell surface by sortase rec-
ognizing an NVQTG motif [30]. In this study, we devel-
oped a FRET-based assay to demonstrate that SrtB of C.
difficile recognizes and cleaves the (S/P)PXTG motif be-
tween the threonine and glycine residues, and that cleav-
age is dependent on a single cysteine residue at position
209. SrtBΔN26 does not appear to cleave the S. aureus
SrtA and SrtB motifs, LPXTG and NPQTN, respectively,
nor the NVQTG motif in vitro, suggesting that CbpA
from C. difficile may be attached to the cell surface by
another mechanism.
The FRET-based assay enabled us to determine kinetic
parameters for the recombinant C. difficile SrtB. Although
the catalytic activity appears low, low catalytic efficiency is
observed for most sortases in vitro [40,51]. The kinetic
and cleavage data we report for SrtBΔN26 is consistent with
this trend. In vivo, the sorting motifs are part of a larger
protein, and the transpeptidation substrates are part
of a cell wall precursor or mature peptidoglycan [5,6,39].
The transpeptidation reaction has been observed in vitro
for sortases from bacteria with a Lys-type peptidog-
lycan, where cross-linking occurs through a peptide
Figure 6 SrtBΔN26 cleaves FRET peptides between T and G residues. MALDI analysis of FRET reaction products revealed a fragment of mass
889.46, corresponding to the predicted mass of d-PVPPKT-OH (top) when d-PVPPKTGDS-e was incubated with SrtBΔN26. This fragment was absent
in the mock treated peptide sample (bottom), indicating that SrtBΔN26 cleaves the d-PVPPKTGDS-e between the T and G residues.
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bridge [52,53] such as S. aureus and Streptococcus species
[4,40,54], but not for bacteria with Dap-type peptidoglycan
such as Bacillus with direct cross-linkages through m-
diaminopimelic acid [55]. The likely cell wall anchor
of the C. difficile SrtB substrates is the diaminopime-
lic acid cross-link [56], similar to Bacillus. When trans-
peptidation is observed in vitro, the cleavage efficiency of
sortase increases.
This study revealed that recombinant SrtBΔN26 cleaves
the (S/P)PXTG motifs with varying levels of efficiency,
cleaving the sequences PPKTG and SPQTG with the
greatest efficiency. Apparent preferential cleavage effi-
ciency of certain substrate sequences in vitro has been
observed in other sortases. For example, in B. anthracis,
BaSrtA cleaves LPXTG peptides more readily than a
peptide containing the sequence LPNTA [15]. The bio-
logical significance of this peptide sequence preference is
unknown.
Small-molecule inhibitors with activity against SrtA
and SrtB have been reported that prevent cleavage of
fluorescently-labelled peptide compounds by sortase in
vitro [57]. These compounds inhibit cell adhesion to
fibronectin, yet, they have no effect on in vitro growth.
Inhibitors tested against SrtA, SrtB and SrtC in B. anth-
racis irreversibly modified the active cysteine residue
[58]. Several compounds identified in this study had an
inhibitory effect on C. difficile SrtB activity. However,
these lead compounds had no direct effect on in vitro C.
difficile growth (data not shown), which is consistent
with observations in S. aureus [57]. Inhibition of bacter-
ial growth is not considered vital in the development of
sortase-based drug therapies. In both Staphylococcus and
Bacillus, sortase inhibitors show good suitability for fur-
ther development as therapeutics despite their lack of
bactericidal activity. When mice challenged with S. aureus
were treated with sortase inhibitor compounds, infection
rates and mortality were reduced [59], despite these com-
pounds having no effect on staphylococcal growth [57].
The use of in silico approaches such as the LeadBuilder
method employed by this study to screen databases of pu-
tative small-molecule inhibitors for further analysis has
been validated. Further analysis of the structural simi-
larities between the hit compounds could lead to a re-
finement of SrtB inhibitor design and increased potency
in vitro.
Conclusions
In conclusion, we demonstrate that C. difficile encodes
a single sortase, SrtB, with in vitro activity. We have
confirmed the C. difficile SrtB recognition sequence as
(S/P)PXTG, and show that C. difficile SrtB cleaves the
(S/P)PXTG motif within peptides between the threonine
and glycine residues. The cysteine residue within the
predicted active site is essential for activity of the en-
zyme, and the cleavage of fluorescently-labelled peptides
can be inhibited by MTSET, a known cysteine protease
inhibitor. SrtB inhibitors identified through our in silico
screen show a greater level of efficacy then MTSET at
inhibiting the protease activity of C. difficile SrtB. Such
inhibitors provide a significant step in successfully iden-
tifying C. difficile SrtB inhibitor compounds, which can
be further refined to enhance their efficacy, and may
Figure 7 Kinetic parameters of SrtBΔN26. In order to determine
the in vitro kinetic parameters of SrtBΔN26 for the SPKTG and PPKTG
motifs, we performed a kinetic analysis of the sortase-catalyzed
hydrolysis reaction. A. Progress curves of the SrtBΔN26-catalyzed
hydrolysis reactions at various concentrations of d-SDSPKTGDN-e
[8 (blue ●), 10 (green ▪), 20 (red ▲), 40 (teal▼), 80 (purple ♦), 160
(yellow ), 200 (black ★), and 240 μM (blue +). The steady state
rate (V) was determined by fitting the data to a linear function.
B. Plot of V against the concentration of the peptide [S]. Nonlinear
regression of these data fitted to Equation 1 resulted in a Km of
74.7 ± 48.2 μM for d-SDSPKTGDN-e. SrtBΔN26 is subject to substrate
inhibition at peptide concentrations > 30 μM, which is not expected
to be physiologically relevant.
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contribute towards the development of novel selective
therapeutics against CDI.
Methods
Bacterial culture
C. difficile strain 630 [24] was cultured on Brazier’s
agar (BioConnections) supplemented with 4% egg yolk
(BioConnections) and 1% defibrinated horse blood (TCS
Biosciences Ltd.). Liquid cultures were grown in brain
heart infusion broth (Oxoid Ltd.) supplemented with
0.05% L-cysteine (BHIS broth). All media was supple-
mented with C. difficile antibiotic supplement (250 μg/ml
D-cycloserine and 8 μg/ml cefoxitin, BioConnections). C.
difficile cultures were incubated at 37°C for 24–48 hours
in a Whitley MG500 anaerobic workstation (Don Whitley
Scientific Ltd.).
One Shot Top10® (Invitrogen) and XL-1 Blue (Agilent)
Escherichia coli were used for all cloning steps, and
Figure 8 SrtBΔN26 activity can be inhibited by rationally designed inhibitors. The proprietary LeadBuilder virtual-screening method
(Domainex Ltd) was used to screen a database of 80,000 potential protease inhibitors, PROTOCATS, with pharmacophoric and docking filters
derived from analysis of the BaSrtB crystal structure [28]. A. Space filling model showing one of the hit compounds fitting into the active site of
BaSrtB and interacting with the catalytic cysteine residue. B. MTSET and the hits from the virtual screen were tested in the FRET-based assay at
varying concentrations to screen for inhibition of SrtBΔN26 mediated cleavage of d-PVPPKTGDS-e. The most effective compounds were LSHTM40,
LSHTM50, and LSHTM52, which had IC50 values of 63.1 ± 8.8, 60.1 ± 4.7 and 44.1 ± 6.9 μM, respectively. The IC50 for MTSET was 286.7 ± 16.6 μM,
indicating its inhibitory effect on SrtBΔN26 is less potent than the three identified compounds.
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NiCo21(DE3) E. coli (NEB) was used for the expression
of recombinant proteins [60]. E. coli strains were
grown at 37°C on Luria-Bertani (LB) agar (Novagen) or
in LB broth (Difco). Media was supplemented with
100 μg/ml ampicillin or 50 μg/ml kanamycin as required.
Genomic DNA isolation
Genomic DNA was isolated from C. difficile strain 630
[24,61] by phenol chloroform extraction as previously
described [29] and used as a template for cloning. The
annotated genome sequences from C. difficile strains
R20291 and CD196 (RT027) [29], M68 and CF5 (RT017)
[20], M120 (RT078) [20], and CD305 (RT023) (unpub-
lished, Wellcome Trust Sanger Institute) were used for
analysis.
Identification of sortase substrates
All proteins encoded by C. difficile strain 630 [24,61]
were searched for the patterns (S/P)PXTG [11] and
NVQTG [30] positioned 17–45 amino acid residues
from the C-terminus [31]. The resulting candidate pro-
tein list was assessed for the known features of a sortase
substrate: (i) a suitable N-terminal signal peptide se-
quence, as predicted by SignalP 4.1 Server (http://www.
cbs.dtu.dk/services/SignalP/) [62], (ii) a potential trans-
membrane segment following the C-terminal “LPXTG-
like” sequence, as predicted by TMHMM Server v. 2.0
(http://www.cbs.dtu.dk/services/TMHMM/) [63], and (iii)
at least two consecutive basic residues (arginine or lysine)
at the C-terminus [31-33].
Genetic manipulation
A list of primers and plasmids used in this study can
be found in Tables 4 and 5, respectively. The coding
sequence for srtB (CD630_27180) was codon-optimized
for expression in E. coli by Celtek Bioscience, LLC
(Nashville, TN, USA). The resulting fragment was cloned
into the NcoI/XhoI sites of pET28a using primers pET_3
and pET_4 to create pET28a-srtB. To improve soluble
SrtB yield, the N-terminal transmembrane anchor domain
(residues 2–25) was replaced with a six-histidine tag. The
truncated gene srtBΔN26 was amplified from pET28a-srtB
using primers pET_17 and pET_16, and cloned into the
NcoI/XhoI sites of pET28a to create pET28a-srtBΔN26.
The mutant protein SrtBΔN26,C209A was generated using
the QuikChange Site-Directed Mutagenesis kit (Agilent)
in accordance with the manufacturer’s instructions using
pET28a-srtBΔN26 as a template and primers C209A and
C209A_antisense. Successful construction of recombinant
plasmids was confirmed by DNA sequencing using pri-
mers T7F and T7R (Source BioScience).
RT-PCR analysis
Total RNA was isolated from C. difficile 630 grown in
BHIS at early exponential phase (t = 3 hours, OD600 =
0.4-0.5), late exponential phase (t = 5 hours, OD600 = 0.8-
0.9), and stationary phase (t = 24 hours, OD600 = 0.6-0.8)
using RNAprotect Bacteria Reagent (Qiagen) and the
FastRNA Pro Blue Kit (MP Biomedicals LLC., Illkirch,
Table 3 Structure of most effective inhibitors of SrtBΔN26
Compound Structure IC50
LSHTM-0040 63.1 ± 8.8 μM
LSHTM-0050 60.1 ± 4.7 μM
LSHTM-0052 44.1 ± 6.9 μM
Table 4 Primers used in this study
Primer Sequence
pET_3 gatattccatggatgaagaaactgtaccgtatcgttatc
pET_4 gatgagctcgaggatcagacgaccgtggataacc
pET_17 gatataccatggatgcaccaccaccaccaccactctaaactgaccaaata
caaccacgacac
pET_16 gatgagctcgagttagatcagacgaccgtggataac
C209A tcgttaccctgtctaccgccacctacgaattcgacg
C209A_antisense cgtcgaattcgtaggtggcggtagacagggtaacga
T7F taatacgactcactataggg
T7R gctagttattgctcagcgg
Table 5 Plasmids used in this study
Plasmid Description Reference
pQE30Xa- srtB Codon optimized srtB,
synthesized and cloned
in pQE30xa
Obtained from
Celtek Bioscience,
LLC
pET28a Commercial protein
expression vector
Provided by
Neil Fairweather
pET28a- srtB Codon optimized srtB
cloned in pET28a
This work
pET28a- srtBΔN26 srtB with residues 2–25
replaced with a
six-histidine tag
This work
pET28a- srtBΔN26,C209A Same as above, with
C209A substitution
This work
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France) in accordance with the manufacturer’s instruc-
tions. Genomic DNA was removed from total RNA sam-
ples using TURBO DNase (Life Technologies). Equal
amounts of RNA were reverse transcribed into comple-
mentary DNA (cDNA) for expression analysis. Briefly,
one μg random primers (Invitrogen) and 40 units RNa-
sin Plus RNase inhibitor (Promega) was added to one μg
RNA in a final volume of 10 μl, and incubated at 65°C
for 10 min followed by room temperature for 30 min.
The following first-strand mixture was added for cDNA
synthesis: four μl of 5x first-strand buffer (Invitrogen),
two μl 0.1 M DTT (Invitrogen), two μl 10 mM dNTP
mix (New England BioLabs), and 1.5 μl Superscript II
(Invitrogen). The reaction mixture was incubated at
25°C for 10 minutes, 42°C for 1 h, and finally 70°C
for 15 minutes. RT-PCRs were performed with gene spe-
cific primers (Additional file 2: Table S1) using cDNA as a
template.
Purification of recombinant protein
Expression constructs were transformed into E. coli
NiCo21(DE3) (NEB). Cultures grown at 37°C were in-
duced for expression with 1 mM IPTG when the OD600
reached 0.6, and harvested after 5 hours. Cell pellets were
resuspended in lysis buffer [1× Bugbuster (Novagen),
50 mM NaH2PO4, 300 mM NaCl, 40 mM imidazole,
1 mM DTT, 1 mg/ml lysozyme, and 25 U/ml Benzonase
nuclease (Novagen) (pH 7.5)]. Lysates were sonicated on
ice for 2 min (15 sec on/off) at 50% Vibra Cell™ high in-
tensity ultrasonic processor (Jencon, Leighton Buzzard,
Bedfordshire, UK) before centrifugation at 10,000 rpm for
45 min. The supernatant was passed through a 0.22 μM
filter before applying to a 1 ml HisTrap HP column
(GE Healthcare), pre-equilibrated with buffer (50 mM
NaH2PO4, 300 mM NaCl, 40 mM imidazole, 1 mM DTT,
pH 7.5). SrtBΔN26 was eluted with an imidazole gradient
(40 – 500 mM) over 25 column volumes. Fractions con-
taining SrtBΔN26 (as identified by SDS-PAGE) were pooled
and injected onto a HiLoad 16/60 Superdex 200 column
(GE Healthcare) pre-equilibrated with buffer F (5 mM
CaCl2, 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM
DTT). Eluted fractions containing SrtBΔN26 were pooled
and concentrated using an Amicon Ultra-15 (10 kDa) cen-
trifuge filter unit (Millipore). Protein samples were quanti-
fied using Bradford reagent (Thermo Scientific) and
analyzed by SDS-PAGE. The mutant protein SrtBΔN26,C209A
was expressed and purified following the above method.
Expression of SrtBΔN26 and SrtBΔN26,C209A was confirmed
by MALDI fingerprinting.
Immunoblotting
Samples were resolved on Novex NuPage 10% Bis-Tris
SDS-PAGE gels (Invitrogen) before transferring to Hybond-
C Extra nitrocellulose (GE Healthcare). Membranes were
probed with rabbit antiserum directed against 6xHis-tag
(1:5000, Abcam), followed by goat anti-rabbit IRDye
conjugated secondary antibody (1:7500, LI-COR Bio-
technology). Blots were visualized using an Odyssey
near-infrared imager (LI-COR Biotechnology).
In vitro analysis of sortase activity
SrtBΔN26 activity was monitored using a fluorescence
resonance energy transfer (FRET) assay [58] in buffer F
(5 mM CaCl2, 50 mM Tris–HCl (pH 7.5), 150 mM
NaCl, and 1 mM DTT). Fluorescently self-quenched
peptides tagged with 5-((2-Aminoethyl)amino)naphtha-
lene-1-sulfonic acid (Edans) as a fluorophore and 4-([4-
(Dimethylamino)phenyl]azo)benzoic acid (Dabcyl) as a
quencher [35], and containing the predicted sorting sig-
nals of SrtB were purchased from Protein Peptide Re-
search Ltd and solubilized in DMSO (Table 2). The
FRET-based assay was performed in a final volume of
100 μl buffer F containing 10 μM SrtBΔN26 and 20 μM
fluorogenic peptide in clear-bottomed, black polystyrene
384-well plates (Nunc). Plates were incubated for 48 hours
at 37°C, during which fluorescence (excitation = 340 nm,
emission = 490 nm) was measured using a Spectra-
Max M3 plate reader (Molecular Devices). Five mM 2-
(trimethylamonium)ethylmethanethiosulfonate (MTSET,
Affymetrix) was added to the reaction as indicated. Each
experiment was performed in triplicate with a minimum
of three biological replicates, and the results are presented
as the means and the standard error of the data obtained.
The two-tailed Student’s T-test was used to analyze the
data. MALDI analysis of FRET reaction samples was per-
formed by the Protein and Nucleic Acid Chemistry Facil-
ity (University of Cambridge) to determine exact cleavage
site within each peptide.
Kinetic measurements
Kinetic data for SrtBΔN26 were obtained by incubating
varying concentrations of peptide (8, 10, 20, 40, 80, 160,
200 and 240 μM) with 10 μM SrtBΔN26. All reactions
were performed as described above, with fluorescence
monitored every ten minutes over a 13 hour period. To
correlate fluorescence signal, expressed as arbitrary rela-
tive fluorescence units (RFU), with the concentration of
product formed, standard curves of the fluorophore
Edans were collected. The linear segment of the fluoro-
phore standard curve generated a conversion ratio of
703.9 RFU/ μM Edans. Initial velocities (V) were de-
termined from the progress curves and plotted against
substrate concentration [S]. The data were fitted to a
modified version of the Michaelis-Menten equation in-
corporating substrate inhibition using SciPy 0.11.0 in
Python 2.7.3, where Vmax is the maximal enzymatic vel-
ocity, Km is the Michaelis constant, and Ki is the inhi-
bitor dissociation constant for unproductive substrate
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binding. All data points were collected in triplicate, and
the overall assay was run in duplicate.
Identification of SrtB inhibitors
The proprietary LeadBuilder virtual screening method
(Domainex, Ltd) was used to interrogate a database
(PROTOCATS) of 80,000 potential compounds which
had been pre-selected as protease inhibitors. The vir-
tual screening protocol used pharmacophoric and docking
filters derived from analysis of the BaSrtB crystal structure
(with which the C. difficile SrtB shows 70% identity and
90% similarity at the active site). Sixty-two compounds
identified in this screen as potential SrtB inhibitors were
obtained from Enamine, ChemBridge, and Key Organics,
and solubilized in DMSO. Selected compounds and
MTSET were incubated with 10 μM SrtBΔN26 at a range
of concentrations in the FRET-based assay conditions
described above, so that final DMSO concentrations
were ≤ 3.75%, a concentration shown to have no signifi-
cant effect on control fluorescence (data not shown). IC50
values were determined by non-linear least squares fit to a
four parameter sigmoidal function using SciPy 0.11.0 in
Python 2.7.3.
Additional files
Additional file 1: Figure S1. RT-PCR analysis in C. difficile strain 630 of
CD2718 and its predicted substrates. PCR reactions were performed with
630 cDNA that was prepared from cultures grown to early exponential
(E), late exponential (L) and stationary phase (S). M = Hyperladder I
(Bioline), G = 630 genomic DNA, W = dH2O. A “+“indicates cDNA reaction
with added reverse transcriptase, “-“ indicates cDNA reaction without
added reverse transcriptase (control for DNA depletion of RNA sample).
Additional file 2: Table S1. Primers used for RT-PCR analysis.
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